Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADA | P00813 | 3/20 | 0.45 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.36 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.33 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.33 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25810956 | 0.91 | SLC2A1 (0.46) | ADASLC2A1PDE4BTLR7SLC29A1 | |
| SCHEMBL23619425 | 0.84 | ADA (0.42) | ADASLC2A1PDE4BTLR8 | |
| SCHEMBL25811616 | 0.78 | ADA (0.33) | ADA | |
| SCHEMBL13482934 | 0.78 | NCF1 (0.37) | ADA | |
| SCHEMBL24222061 | 0.77 | DHFR (0.43) | ADASLC2A1PDE4B | |
| SCHEMBL24239193 | 0.75 | ADA (0.50) | ADAPDE4B | |
| SCHEMBL23619314 | 0.75 | HRH4 (0.45) | ADAPDE4BTLR8 | |
| SCHEMBL21078676 | 0.71 | SLC2A1 (0.49) | ADASLC2A1PDE4B | |
| SCHEMBL4235557 | 0.70 | ADA (0.39) | ADA | |
| SCHEMBL22071859 | 0.70 | DYRK1A (0.37) | ADAPDE4BTLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210206796-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2021-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210206796-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | STING1, CGAS, IFNAR1 | ADA 147/4885SLC2A1 3933/4885PDE4B 198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.